250 related articles for article (PubMed ID: 37760438)
1. Topical and Intralesional Immunotherapy for Melanoma In Situ: A Review.
Martínez-Fernández S; González-Sixto B; Espasandín-Arias M; Soto-García D; Flórez Á
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760438
[TBL] [Abstract][Full Text] [Related]
2. Interventions for melanoma in situ, including lentigo maligna.
Tzellos T; Kyrgidis A; Mocellin S; Chan AW; Pilati P; Apalla Z
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010308. PubMed ID: 25526608
[TBL] [Abstract][Full Text] [Related]
3. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery.
Erickson C; Miller SJ
Int J Dermatol; 2010 May; 49(5):482-91. PubMed ID: 20534080
[TBL] [Abstract][Full Text] [Related]
4. Immunocryosurgery as monotherapy for lentigo maligna or combined with surgical excision for lentigo maligna melanoma.
Matas-Nadal C; Sòria X; García-de-la-Fuente MR; Huerva V; Ortega E; Vilardell F; Gatius S; Casanova JM; Martí RM
J Dermatol; 2018 May; 45(5):564-570. PubMed ID: 29430695
[TBL] [Abstract][Full Text] [Related]
5. Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature.
Vaienti S; Calzari P; Nazzaro G
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2187-2215. PubMed ID: 37615838
[TBL] [Abstract][Full Text] [Related]
6. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature.
Ellis LZ; Cohen JL; High W; Stewart L
Dermatol Surg; 2012 Jun; 38(6):937-46. PubMed ID: 22338583
[TBL] [Abstract][Full Text] [Related]
7. Topical imiquimod immunotherapy in the management of lentigo maligna.
Powell AM; Russell-Jones R; Barlow RJ
Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
[TBL] [Abstract][Full Text] [Related]
8. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):T407-T412. PubMed ID: 35623739
[TBL] [Abstract][Full Text] [Related]
9. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):407-412. PubMed ID: 35431054
[TBL] [Abstract][Full Text] [Related]
10. Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.
Donigan JM; Hyde MA; Goldgar DE; Hadley ML; Bowling M; Bowen GM
JAMA Dermatol; 2018 Aug; 154(8):885-889. PubMed ID: 29847610
[TBL] [Abstract][Full Text] [Related]
11. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
12. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
[TBL] [Abstract][Full Text] [Related]
13. Clinical and histologic features associated with lentigo maligna clearance after imiquimod treatment.
Kwak R; Joyce C; Werchniak AE; Lin JY; Tsibris HC
J Dermatolog Treat; 2022 Jun; 33(4):1995-1999. PubMed ID: 34315342
[TBL] [Abstract][Full Text] [Related]
14. An Algorithm for the Management of Residual Head and Neck Melanoma In Situ Using Topical Imiquimod: A Pilot Study.
Tsay C; Kim S; Norwich-Cavanaugh A; Hsia HC; Narayan D
Ann Plast Surg; 2019 Apr; 82(4S Suppl 3):S199-S201. PubMed ID: 30855388
[TBL] [Abstract][Full Text] [Related]
15. Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna.
Robinson M; Primiero C; Guitera P; Hong A; Scolyer RA; Stretch JR; Strutton G; Thompson JF; Soyer HP
Dermatology; 2020; 236(2):111-116. PubMed ID: 31639788
[TBL] [Abstract][Full Text] [Related]
16. Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review.
Neumann I; Patalay R; Kaushik M; Timlin H; Daniel C
Eye (Lond); 2023 Feb; 37(3):408-414. PubMed ID: 35835989
[TBL] [Abstract][Full Text] [Related]
17. Lentigo Maligna Treatment-An Update.
Ungureanu L; Vasilovici AF; Trufin II; Apostu AP; Halmágyi SR
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731056
[TBL] [Abstract][Full Text] [Related]
18. Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.
Friedman EB; Scolyer RA; Williams GJ; Thompson JF
Adv Ther; 2021 Jul; 38(7):3506-3530. PubMed ID: 34047915
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment.
Tio DCKS; van Montfrans C; Ruijter CGH; Hoekzema R; Bekkenk MW
Acta Derm Venereol; 2019 Sep; 99(10):884-888. PubMed ID: 31233181
[TBL] [Abstract][Full Text] [Related]
20. Role of In Vivo Reflectance Confocal Microscopy in the Analysis of Melanocytic Lesions.
Serban ED; Farnetani F; Pellacani G; Constantin MM
Acta Dermatovenerol Croat; 2018 Apr; 26(1):64-67. PubMed ID: 29782304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]